Evidence map›Paper›PMID 36156926›Full record

ArticleWorld journal of gastroenterology2022

Previous hepatitis B viral infection-an underestimated cause of pancreatic cancer.

Sergey Batskikh, Sergey Morozov, Alexey Dorofeev, Zanna Borunova, Dmitry Kostyushev, Sergey Brezgin, Anastasiya Kostyusheva, Vladimir Chulanov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. [Occurrence risk of extrahepatic liver tumor with hepatitis B virus infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sergey BatskikhDepartment of Hepatology, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia.
Sergey MorozovDepartment of Gastroenterology, Hepatology and Nutrition, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow 115446, Russia. morosoffsv@mail.ru.
Alexey DorofeevDepartment of Scientific and Clinical Laboratory Research, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia.
Zanna BorunovaDepartment of Scientific and Clinical Laboratory Research, Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow 111123, Russia.
Dmitry KostyushevLaboratory of Genetic Technologies, Sechenov University, Moscow 119435, Russia.
Sergey BrezginLaboratory of Genetic Technologies, Sechenov University, Moscow 119435, Russia.
Anastasiya KostyushevaLaboratory of Genetic Technologies, Sechenov University, Moscow 119435, Russia.
Vladimir ChulanovLaboratory of Genetic Technologies, Sechenov University, Moscow 119435, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe etiology of pancreatic cancer remains unclear. This limits the possibility of prevention and effective treatment. Hepatitis B virus (HBV) is responsible for the development of different types of cancer, but its role in pancreatic cancer is still being discussed.

aimTo assess the prevalence of previous HBV infection and to identify viral biomarkers in patients with pancreatic ductal adenocarcinoma (PDAC) to support the role of the virus in etiology of this cancer.

methodsThe data of 130 hepatitis B surface antigen-negative subjects were available for the final analysis, including 60 patients with PDAC confirmed by cytology or histology and 70 sex- and age-matched controls. All the participants were tested for HBV biomarkers in blood [antibody to hepatitis B core antigen (anti-HBc), antibody to hepatitis B surface antigen (anti-HBs) and HBV DNA], and for those with PDAC, biomarkers in resected pancreatic tissues were tested (HBV DNA, HBV pregenomic RNA and covalently closed circular DNA). We performed immunohistochemistry staining of pancreatic tissues for hepatitis B virus X antigen and Ki-67 protein. Non-parametric statistics were used for the analysis.

resultsAnti-HBc was detected in 18/60 (30%) patients with PDAC and in 9/70 (13%) participants in the control group (

conclusionWe found significantly higher risks of PDAC in anti-HBc-positive patients. Detection of viral replication and hepatitis B virus X protein expression in the tumor tissue prove involvement of HBV infection in pancreatic cancer development.

Indexed as

Carcinoma, Pancreatic DuctalHepatitis BPancreatic NeoplasmsDNA, CircularDNA, ViralHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B virusHumansKi-67 AntigenRNADNA, CircularDNA, ViralHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensKi-67 AntigenRNAHepatitis B virusOccult hepatitis B virus infectionPancreatic cancerPancreatic ductal adenocarcinomaPrevious hepatitis B

Identifiers

PMID36156926
PMCPMC9476854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.